rs111227877 - CCR3 - UQCRC2P1
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association studies of antidepressant class response and treatment-resistant depression - Unknown journal (n.d.) · Unknown authors · PubMed 33106475
ABSTRACT: The "antidepressant efficacy" survey (AES) was deployed to > 50,000 23andMe, Inc. research participants to investigate the genetic basis of treatment-resistant depression (TRD) and non-treatment-resistant depression (NTRD). Genome-wide association studies (GWAS) were performed, including TRD vs. NTRD, selective serotonin reuptake inhibitor (SSRI) responders vs. non-responders, serotonin-norepinephrine reuptake inhibitor (SNRI) responders vs. non-responders, and norepinephrine-dopamine reuptake inhibitor responders vs. non-responders. Only the SSRI association reached the genome-wide significance threshold (p < 5 × 10−8): one genomic region in RNF219-AS1 (SNP rs4884091, p = 2.42 × 10−8, OR = 1.21); this association was also observed in the meta-an
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
antidepressant response prediction Moderate
This variant is associated with differential antidepressant response and treatment-resistant depression risk.
If considering antidepressant therapy, discuss genetic profile with your psychiatrist or physician.